Quick Answer
Milestone Pharmaceuticals Inc. reported Cash And Cash Equivalents At Carrying Value of $73.05 million for the year ending 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +188.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $71.24 million | Q2 2019: $110.82 million | Q3 2019: $106.50 million | Q1 2020: $101.82 million | Q2 2020: $53.43 million | Q3 2020: $46.91 million | Q1 2021: $71.86 million | Q2 2021: $97.79 million | Q3 2021: $111.43 million | Q1 2022: $92.24 million | Q2 2022: $63.24 million | Q3 2022: $37.29 million | Q1 2023: $73.95 million | Q2 2023: $32.59 million | Q3 2023: $9.88 million | Q1 2024: $10.13 million | Q2 2024: $13.26 million | Q3 2024: $12.80 million | Q1 2025: $45.09 million | Q2 2025: $42.50 million | Q3 2025: $46.69 million.
- Over the full 8 years of available data (2018 to 2025), Milestone Pharmaceuticals Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 15.0%.
- Historical annual values: Fiscal year 2025: $73.05 million | Fiscal year 2024: $25.31 million | Fiscal year 2023: $13.76 million | Fiscal year 2022: $7.64 million | Fiscal year 2021: $114.14 million | Fiscal year 2020: $72.31 million | Fiscal year 2019: $119.82 million | Fiscal year 2018: $85.95 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: